FDA-process and commercialization on track. New study results confirm the potential. Year-End Report (May-January 2018/2019)

SEK thousands                         Q4 18/19    Q4 17/18 May-April 18/19 May-April 17/18 Net sales                                               1,715           1,433                 3,005                    2,723 Operating profit (loss)                        -8,569          -4,132              -21,718                -17,956 Loss for the period                              -8,631          -4,176              -21,556                -18,010 Earnings per share, after dilution        -0.47            -0.24                  -1.18                     -1.01

2020-02-19T13:39:41+00:00 June 14th, 2019 08:00|Regulatory|
Read More

FDA-process och kommersialisering enligt plan. Nya studiedata bekräftar potentialen. Bokslutskommuniké maj-april 2018/2019

kSEK                                         kv 4 18/19 kv 4 17/18 maj-apr 18/19        maj-apr 17/18 Nettoomsättning                              1 715         1 433          3 005          2 723 Rörelseresultat                                  -8 569        -4 132        -21 718      -17 956 Periodens resultat                             -8 631        -4 176        -21 556      -18 010 Resultat per aktie ef utspäd             -0,47          -0,24          -1,18           -1,01

2020-02-19T13:39:39+00:00 June 14th, 2019 08:00|Regulatory|
Read More
In the United States and Japan DiviTum® is currently available for research purposes only.
All information, without limitation, on this website is not intended to be used for medical diagnosis or treatment. Information provided on this website does not constitute medical or other professional advice. DiviTum® is CE-labelled, registered by the Swedish Medical Products Agency.

Copyright 2017 Biovica | All Rights Reserved